Biogen sees bright future in MS combo therapies Pharma Times He also highlighted the progress being made on a pegylated version of its blockbuster Avonex (interferon beta-1a) and Abbott-partnered daclizumab,. Asked which of the current pipeline compounds he considered currently to be most promising, Dr Sandrock ... |
